Patents Examined by Delbert R. Philips
  • Patent number: 4916118
    Abstract: The present invention relates to pharmaceutical administration systems containing phosphatidylserine and phosphatidylcholine or phosphatidylethanolamine derivatives in the form of liposomes which encapsulate chemotactic peptides such as N-formyl-L-methionyl-L-leucyl-L-phenylalanine. The liposomes are prepared by conventional dispersion methods. The pharmaceutical administration systems when applied in the form of liposomes stimulate macrophage activity which is especially useful in the cancer therapy for combating metastatic tumor cells and for treatment of chronic infections.
    Type: Grant
    Filed: August 12, 1987
    Date of Patent: April 10, 1990
    Assignee: Board of Regents, The University of Texas System
    Inventors: Isaiah J. Fidler, Kiyoshi Morikawa, Rajiv Nayar
  • Patent number: 4716147
    Abstract: Novel synthetic atrial peptides are provided with enhanced natriuretic properties by substituting one or two arginine residues for the N-terminal ser-ser in atriopeptins I, II and III and their physiologically acceptable salts, esters and amides.
    Type: Grant
    Filed: March 27, 1986
    Date of Patent: December 29, 1987
    Assignee: Monsanto Company
    Inventors: Foe S. Tjoeng, Kam F. Fok, Steven P. Adams
  • Patent number: 4525300
    Abstract: An antibody of a human leukemia virus-related peptide obtained by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide selected from the group consisting of:(a) a peptide represented by formula (1):H-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu-H (1)(b) a peptide represented by formula (2):R-Ile-Pro-His-Pro-Lys-Asn-Ser-Ile-Gly-Gly-Glu-Val-OH (2)wherein R is the same as drefined above;(c) a peptide represented by formula (3):R-Thr-Trp-Thr-Pro-Lys-Asp-Lys-Thr-Lys-Val-Leu-OH (3)wherein R is the same as defined above;(d) a peptide represented by formula (4):H-Val-Val-Gln-Pro-Lys-Lys-Pro-Pro-Pro-Tyr-OH (4)(e) a peptide represented by formula (5):R-Met-Gly-Gln-Ile-Phe-Ser-Arg-Ser-Ala-Ser-Pro-OH (5)wherein R is the same as defined above; and(f) a peptide represented by formula (6):H-Tyr-Pro-Glu-Gly-Thr-Pro-Lys-Asp-Pro-Ile-Leu-Arg-Ser-Leu-OH (6)as a hapten, with a carrier in the presence of a hapten-carrier binding agent.
    Type: Grant
    Filed: September 23, 1983
    Date of Patent: June 25, 1985
    Assignees: Japanese Foundation for Cancer Research, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Mitsuaki Yoshida, Haruo Sugano, Fumio Shimizu, Kenichi Imagawa
  • Patent number: 4515920
    Abstract: Solid phase synthesis of peptides and proteins have been improved by the use of a trifunctional segment, one functional group of which is bound to a solid support, the other two functional groups being available as substrates upon which identical proteins are synthesized.
    Type: Grant
    Filed: April 30, 1984
    Date of Patent: May 7, 1985
    Assignee: The Rockefeller University
    Inventor: Bruce W. Erickson
  • Patent number: 4293482
    Abstract: A-30912A nucleus, which is prepared by enzymatic deacylation of an antibiotic selected from A-30912 factor A, tetrahydro-A-30912A, and aculeacin A using an enzyme produced by the Actinoplanaceae, preferably by Actinoplanes utahensis. A-30912A nucleus and salts thereof are useful intermediates to prepare new semi-synthetic antifungal agents.
    Type: Grant
    Filed: August 25, 1980
    Date of Patent: October 6, 1981
    Assignee: Eli Lilly and Company
    Inventors: Bernard J. Abbott, David S. Fukuda
  • Patent number: 4276282
    Abstract: The present invention relates to processes for an easily applicable industrial production of interferon and the possibilities of the products for preventing and treating interferonsensitive diseases.The process easily produces a large amount of interferon and transplanting established human cells to other warm-blooded animals or inoculating the cells in a diffusion chamber and multiplying the cells therein while allowing the animals to supply the cells with their nutrient body fluids, then exposing in vivo or in vitro the resultant cells to the action of interferon inducer. The present invention is also based on the discovery that the interferon obtained by the present method is an effective and superior preparation for preventing and treating interferon-sensitive diseases.
    Type: Grant
    Filed: January 22, 1979
    Date of Patent: June 30, 1981
    Assignees: Ken Hayashibara, Shin Ashida
    Inventors: Kaname Sugimoto, Shokichi Yuen
  • Patent number: 4049829
    Abstract: The present invention concerns as new industrial products, hydroxy-thioalkanes of the formula:Ti Ho--A--S--(CH.sub.2).sub.n --S--A--OHwhere n is an integer from 5 to 15 and A is a straight or branched C.sub.2 -C.sub.6 hydrocarbon chain which may also comprise an OH group.The compounds of formula I are useful in therapeutics, notably as hypolipemiant and hypocholesterolemiant agents.
    Type: Grant
    Filed: September 18, 1975
    Date of Patent: September 20, 1977
    Assignee: Societe anonyme dite: Laboratoire L. Lafon
    Inventor: Louis Lafon
  • Patent number: 4028318
    Abstract: Chromogenic substrates for serine proteases, represented by the formula:R.sub.1 -A.sub.1 -A.sub.2 -Gly-Arg-NH-R.sub.2or its salts, where R.sub.1 is hydrogen or alkanoyl having from 1 to 12 carbon atoms or cyclohexylcarbonyl or benzoyl or benzoyl substituted with one or two halogen atoms, methylamine or phenyl groups or benzene sulphonyl or toluenesulphonyl, R.sub.2 is nitrophenyl or naphthyl or nitronaphthyl or methoxynaphthyl or quinolyl or nitroquinolyl, A.sub.1 is a single bond or one of the amino acids Gly, Ala, Val, Leu, Ileu, Pro, Met, Phe or Tyr, and A.sub.2 is one of the amino acids Glu, Gln, Asp, or Asn.
    Type: Grant
    Filed: November 14, 1975
    Date of Patent: June 7, 1977
    Assignee: A B Kabi
    Inventors: Leif Erik Aurell, Karl Goran Claeson